Energy Transfer: A Chronicle of Incremental Yield

The recent pronouncement of another distribution increase is not merely a numerical event; it is a symptom. A symptom of a system wherein steady, predictable returns are increasingly rare, and where the pursuit of exponential growth often eclipses the fundamental need for durable, sustainable yield. Energy Transfer, with its commitment to incrementalism, appears, at least superficially, to offer a respite from this relentless pursuit of the spectacular.

A Spot of Trouble? Markets & the Trump Years

Of course, it hasn’t been entirely champagne and canapés. The little unpleasantness of early 2020 – that pandemic, you know – caused a bit of a wobble. A 34% drop in the S&P 500. Ghastly. And then, the tariffs. Oh, the tariffs. A two-day plunge of 10.5%. One felt quite sorry for the traders. Though, naturally, one didn’t express it.

Shifting Currents: Apple, Intel, and the Foundry’s Shadow

The bottleneck, it appears, resides not in the appetite of consumers, but in the capacity of the foundry. TSMC, that Taiwanese behemoth, finds itself stretched thin, burdened by the demands of an industry intoxicated by the promise of artificial intelligence. The very accelerators that propel this new age are, ironically, limiting its reach. A curious paradox, wouldn’t you agree? It is a reminder that even the most advanced enterprises are, at their core, subject to the limitations of earthly logistics.

Buffett’s Oil Gambit: A Dividend Hunter’s Descent

Berkshire Hathaway. The name itself sounds like a conspiracy. They didn’t just buy oil, they inhaled it. Chevron, Occidental… names that used to evoke gas stations and road trips now whisper of fortunes and leverage. Twenty-one billion here, twelve billion there… it’s enough to make a sane man question reality. And then the acquisitions. Dominion Energy’s assets? Snapped up like candy. Cove Point? Another piece of the puzzle. It’s a land grab, a frantic scramble for the black gold before the world supposedly turns green. They’re building a fortress, a dividend-spewing monolith fueled by the planet’s dwindling reserves. And the cash? Oh, the cash pile. They weren’t buying growth stocks; they were hoarding ammunition.

The Illusion of Transformation

The company, once a purveyor of plastic discs, is now presented as a potential analogue to Berkshire Hathaway. This claim warrants scrutiny, not celebration. Mr. Burry’s recent purchase of GameStop shares, while perhaps motivated by a genuine belief in its leadership, feels less like shrewd investment and more like a desperate search for a narrative.

Buffett’s Sweeties: Two Stocks to Stash

Visa isn’t the biggest sweet in Berkshire’s jar, not by a long shot (a mere 0.9% of the total), but it’s a reliable one. Old Buffett was always going on about ‘moats’ – not the watery kind, mind you, but things that keep the competitors at bay. Visa’s moat is its reach. It’s everywhere!

Ephemeral Yields: A Market of Shadows

But does this represent a genuine opportunity for the discerning investor, or merely another gilded cage constructed to ensnare the unwary? The question demands a sober assessment, a peeling back of the layers of hype and illusion.

Dividends? Fine. Whatever.

This AbbVie thing. They’re a “Dividend King.” A king. Seriously? Like they’re royalty because they’ve been handing out a little extra change for fifty years? It’s just… aggressive. But, okay, they’ve been doing it. Fifty years. It’s impressive, I suppose. It means they haven’t completely messed things up for half a century. That’s… a low bar, isn’t it?

Pfizer: A Cautionary Investment

To understand Pfizer is to understand the inherent contradictions of the pharmaceutical industry. It is a capital-intensive undertaking, demanding vast sums for research and development. Regulatory hurdles, while necessary, further inflate costs. Competition is relentless, each company striving for dominance in narrowly defined therapeutic niches. The system is rigged, not by malice, but by its very nature. Patents offer a temporary monopoly, allowing for exorbitant profits, but this advantage inevitably erodes as generic alternatives flood the market. This ‘patent cliff,’ as it is euphemistically termed, is not a bug, but a feature.

Under Armour: A Most Curious Investment

This acquisition, representing a mere 4.2% addition to the insider’s existing portfolio, is, shall we say, a subtle flourish. It lacks the audacity of conviction, yet possesses the intrigue of a carefully considered wager. The absence of directly held shares in this transaction is, in itself, a statement—a quiet declaration of preference for the shadows of indirect ownership.